PharmaDrug Inc said its common shares began trading on the OTCQB Venture Market (OTCQB) in the US on October 19, 2021, under the symbol ‘LMLLF’.
The company noted its shares will continue to trade on the Canadian Securities Exchange (CSE) under the symbol ‘PHRX’.
“We are extremely excited to be posting our shares on the OTCQB, a well-known U.S. Securities platform,” PharmaDrug CEO Daniel Cohen said in a statement.
READ: PharmaDrug hails pre-clinical results on Cepharanthin to treat cancer; eying FDA IND-enabling animal studies in 4Q
“We believe the strategy to increase US investor ownership fits well with the growing focus on biotech research and development as well as the Company's intention to both lead and collaborate on several FDA clinical trials,” Cohen added.
US investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com and can also find information about PharmaDrug and its strategy on its new website, www.pharmadrug.ca.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics, cannabis, and naturally-derived approved drugs.
The company owns 100% of Pharmadrug Production GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics license and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the EU.
It also owns 100% of Super Smart, a Dutch company building a modern adult-use psychedelic retail business with an elevated and educational focus. PharmaDrug recently acquired Sairiyo Therapeutics, a biotech company that specializes in researching and reformulating established natural medicines with the goal of bringing them through regulatory and research-driven clinical trials.
Contact Sean at sean@proactiveinvestors.com